Multinational phase 3 study of first-line cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma

Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumors. The multinational phase 3 COSMIC-312 trial evaluated cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma previously untreated with systemic anticancer therapy. The study found that cabozantinib plus atezolizumab versus sorafenib resulted in better PFS but not OS. The authors conclude that cabozantinib plus atezolizumab might be a treatment option for select patients with advanced hepatocellular carcinoma, but additional studies are needed.